Glioblastoma Multiforme Market: Industry trends, Drugs, Therapies and Analysis by DelveInsight |Genentech, Merck, VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics

 Breaking News
  • No posts were found

Glioblastoma Multiforme Market: Industry trends, Drugs, Therapies and Analysis by DelveInsight |Genentech, Merck, VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics

Glioblastoma Multiforme Market: Industry trends, Drugs, Therapies and Analysis by DelveInsight |Genentech, Merck, VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics

Glioblastoma Multiforme Market

Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma.

DelveInsight’s ‘Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Key Findings of Glioblastoma Multiforme Market Report:

This section includes a glimpse of the Glioblastoma Multiforme (GBM) 7MM market.

  • The market size of GBM in the seven major markets was estimated to be USD 1,005 Million in 2017.
  • The United States accounts for the largest market size of GBM throughout the study period of 2017–2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 629 Million in 2017.
  • Among the EU5 countries, Germany had the highest market size with USD 73 Million in 2017, while Spain had the lowest market size with USD 35 Million.
  • Japan accounted for the second highest market size in the 7 MM during the forecast period of 2020–2030, which was estimated to be USD 82 Million in 2017.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market

 

Scope of the Glioblastoma Multiforme Report :

  • The report covers the descriptive overview of Glioblastoma Multiforme (GBM), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Glioblastoma Multiforme (GBM) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Glioblastoma Multiforme (GBM) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Glioblastoma Multiforme (GBM) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glioblastoma Multiforme (GBM) market.

 

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market

 

Some of Glioblastoma Multiforme Companies are:

  • Genentech  
  • Merck  
  • VBL Therapeutics  
  • Diffusion Pharmaceuticals  
  • Bayer  
  • MedImmune  
  • DNAtrix  
  • Oncoceutics  
  • Karyopharm Therapeutics  
  • Kazia Therapeutics  
  • Aivita Biomedical  
  • Medicenna Therapeutics
  • And Many others

  

Some of Glioblastoma Multiforme Therapies are:

  • Avastin
  • Temodar/Temodal
  • Ofranergene obadenovec (VB-111)
  • Trans Sodium Crocetinate
  • Regorafenib
  • Durvalumab (MEDI4736)
  • Tasadenoturev (DNX-2401)
  • ONC201
  • Selinexor (KPT-330)
  • Paxalisib (GDC-0084)
  • AV-GBM-1
  • MDNA55
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market

 

Table of Contents:

1 Key Insights

2 Glioblastoma Multiforme Market Overview at a Glance

2.1 Market Share (%) Distribution of GBM in 2017

2.2 Market Share (%) Distribution of GBM in 2030

3 Executive Summary of Glioblastoma Multiforme (GBM)

4 Disease Background and Overview: Glioblastoma Multiforme (GBM)

5 Epidemiology and Patient Population

6 Country Wise-Epidemiology of Glioblastoma Multiforme

7 Treatment

8 Treatment Algorithm

9 The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma

10 The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma

11 Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

12 SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma

13 Recognized Establishments

14 Unmet Needs

15 Marketed Drugs

16 Emerging Drugs

17 Glioblastoma Multiforme: 7 Major Market Analysis

18 Market Access and Reimbursement

19 Case Reports

20 KOL Reviews

21 Market Drivers

22 Market Barriers

23 SWOT Analysis

24 Appendix

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight

Request for Detailed TOC @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market

Categories